Nucleic acid therapies: Towards cardiac-specific recombinant adeno-associated viruses (rAAVs) of human origin: Directed evolution and characterization of novel AAV variants isolated from human failing hearts in models with human relevance and relevance fo
| Institution | Universität Heidelberg |
|---|---|
| Projektleiter | Patrick Most |
| Standort | Heidelberg/Mannheim |
| Projektart | Innovation Cluster |
| Fördersumme | € 607.835,00 |
| Beginn | 01.01.2021 |
| Ende | 31.12.2025 |
| Partnerprojekte |
|
Förderkennzeichen
81X2500195
Projektnummer
1326